Biomea Fusion, Inc. Scheduled to Announce Q3 2026 Financial Results
Biomea Fusion, Inc. is set to release its financial results for the third quarter of 2026 on November 3, 2026.
Stocks · News reference
Biomea Fusion shares are trading lower after the company announced Phase 1 GLP-131 clinical trial results for BMF-650.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Piper Sandler Maintains Biomea Fusion With Buy Rating, Adjusts Price Target
Piper Sandler analyst Edward Tenthoff has maintained a 'Buy' rating on Biomea Fusion while lowering the firm's price target for the stock from $7 to $4.
Citizens Reiterates Market Outperform on Biomea Fusion, Maintains $7 Price Target
Citizens analyst Jonathan Wolleben reiterates Biomea Fusion (NASDAQ:BMEA) with a Market Outperform and maintains $7 price target.
State Street, Fastenal And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. futures were mixed. State Street fell 6.4% after missing sales estimates, while Biomea Fusion, Skydance and other stocks slid premarket.
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $4 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $4 price target.
Why Enovix Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Enovix jumps 6.8% after securing a 100,000-unit battery order from a multinational drone maker, with deliveries planned for H1 2027.